Skip to Main Content

Paper Details

Targeting Triple-Negative Breast Cancer by a Novel Proteolysis Targeting Chimera Degrader of Enhancer of Zeste Homolog 2.
ACS Pharmacol Transl Sci
21
2022
EZH2, EZH2 protein, Enhancer, Enhancer of Zeste Homolog 2, Enhancer of zeste homolog 2, MS8815, PRC2, PROTAC, TNBC, TNBC cell lines, TNBC cells, Triple-Negative Breast Cancer, VHL, YM281, patient, polycomb repressive complex 2, primary patient TNBC cells, triple-negative breast cancer, von Hippel-Lindau
Author NameAffiliation
Ling XieUniversity of North Carolina at Chapel Hill
Xian ChenUniversity of North Carolina at Chapel Hill
Jian JinMount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
  • 1 - 3

Datasets

Release 1.2